Pulmonary Vascular and Vasculitic Lung Disease

Pulmonary Embolism (PE)

Clinical features

•    Sudden-onset dyspnoea, pleuritic chest pain

•    Haemoptysis (pulmonary infarction)

•    Tachycardia, tachypnoea

•    Possible hypotension (massive PE)

•    Possible signs of DVT

Investigations

•    Wells score to assess probability:

o    4 "PE likely" CTPA

o    ≤4 "PE unlikely" D-dimer (if positive, proceed to CTPA)

•    ABG: may show hypoxaemia, hypocapnia (due to hyperventilation)

•    ECG: sinus tachycardia, S1Q3T3 pattern (rare)

•    CXR: usually normal; possible wedge-shaped infarct (Hampton’s hump)

Management

•    Anticoagulation:

o    DOACs first line (e.g., apixaban, rivaroxaban)

o    LMWH bridging to warfarin in certain cases (e.g., antiphospholipid syndrome)

•    Thrombolysis for massive PE with haemodynamic instability


Pulmonary Hypertension (PH)

Signs

•    Loud P2 (pulmonary component of second heart sound)

•    Parasternal heave (right ventricular hypertrophy)

•    Right heart failure signs (elevated JVP, hepatomegaly, peripheral oedema)

Causes (WHO classification)

1.    Pulmonary arterial hypertension (PAH) (idiopathic, CTD-related, HIV, portal HTN)

2.    Left heart disease (mitral stenosis, LV dysfunction)

3.    Lung disease or hypoxia (COPD, ILD)

4.    Chronic thromboembolic PH (CTEPH)

5.    Miscellaneous (sarcoidosis, haematological)

Investigations

•    Echocardiogram (screening tool): estimates pulmonary artery systolic pressure

•    Right heart catheterisation: definitive diagnosis

Management

•    Treat underlying cause

•    PAH-specific therapy: endothelin receptor antagonists (bosentan), PDE-5 inhibitors (sildenafil), prostacyclin analogues


Granulomatosis with Polyangiitis (GPA, Wegener’s)

Features

•    Upper respiratory tract: sinusitis, nasal crusting, saddle-nose deformity

•    Lower respiratory tract: nodules (may cavitate), haemoptysis

•    Renal: rapidly progressive GN (haematuria, red cell casts)

Investigations

•    cANCA (PR3) positive (high specificity)

•    Biopsy: necrotising granulomatous inflammation

Management

•    Induction: cyclophosphamide + high-dose steroids

•    Maintenance: azathioprine, methotrexate


Eosinophilic Granulomatosis with Polyangiitis (EGPA, Churg–Strauss)

Features

•    Asthma (almost universal)

•    Peripheral eosinophilia

•    Mononeuritis multiplex

•    Pulmonary infiltrates (transient)

•    Skin purpura

Investigations

•    pANCA (MPO) positive (≈40%)

Management

•    Steroids ± cyclophosphamide if severe


Polyarteritis Nodosa (PAN) & Henoch–Schönlein Purpura (HSP)

PAN

•    Medium-vessel vasculitis

•    Multisystem: renal infarcts (no GN), mesenteric ischaemia, neuropathy

•    HBV association

HSP (IgA vasculitis)

•    Small-vessel vasculitis

•    Classic tetrad:

o    Palpable purpura (legs/buttocks)

o    Arthralgia

o    Abdominal pain

o    Renal involvement (IgA nephropathy)

•    Rare pulmonary involvement: alveolar haemorrhage


Connective Tissue Disease Lung Involvement

•    Rheumatoid arthritis:

o    ILD (UIP pattern most common)

o    Pleural effusions

o    Nodules

•    Systemic sclerosis:

o    ILD (NSIP pattern common)

o    Pulmonary hypertension

•    SLE:

o    Pleural effusions (common)

o    Shrinking lung syndrome

o    Diffuse alveolar haemorrhage


Pulmonary Eosinophilia

Causes

•    Parasitic infections (e.g., Ascaris, Strongyloides)

•    Drugs: nitrofurantoin, NSAIDs, antibiotics

•    ABPA

•    Idiopathic (e.g., simple pulmonary eosinophilia — Loeffler’s)

Clinical features

•    Cough, dyspnoea

•    Peripheral eosinophilia

Management

•    Remove cause

•    Steroids if severe


Extra Revision Pearls

•    Wells score ≥4 straight to CTPA

•    Saddle-nose deformity clue GPA

•    Asthma + eosinophilia think EGPA

•    Loud P2 classic clue for PH on exam

•    HBV link think PAN

•    RA + lower lobe fibrosis consider UIP pattern

•    Pleuritic chest pain + dyspnoea + normal CXR suspect PE

•    Alveolar haemorrhage clues GPA, SLE, HSP

————————————————————————————————————————————————————————————————————————————————————————————————————————-

Author & Educational Disclaimer


Author:

Dr Phillip Cockrell BM FRCP DipClinEd


Dr Phillip Cockrell is a UK Consultant Physician in Internal Medicine, currently working at Queen Alexandra Hospital, Portsmouth University Hospitals NHS Trust. He has previously worked as a registrar across Intensive Care Medicine, Gastroenterology, Cardiology, Stroke Medicine, Acute Medicine, and Respiratory Medicine.


He has held senior leadership roles including Associate Clinical Director of the Acute Medical Unit, Clinical Director of Internal Medicine, and Chief of Medicine. Dr Cockrell has over 15 years’ experience in postgraduate medical education, having lectured extensively across the MRCP syllabus and contributed to MRCP revision teaching and course development.


Dr Cockrell holds a Bachelor of Medicine (BM), Fellowship of the Royal College of Physicians (FRCP), and a Diploma in Clinical Education (DipClinEd). His teaching approach is based on structured consolidation of complex medical topics to support efficient and effective revision for postgraduate examinations.


Purpose of this content:

The material on this page is intended solely for educational purposes to support revision for the MRCP (UK) Part 1 examination. It reflects examination-relevant principles of internal medicine and is designed to aid learning and pattern recognition.


Medical disclaimer:

This content is designed for postgraduate medical examination revision and does not constitute medical advice, diagnosis, or treatment guidance and must not be used as a substitute for professional clinical judgement, local guidelines, or specialist consultation. Clinical decisions should always be made in the context of individual patient circumstances and current national guidance.